Fredun Pharmaceuticals Ltd (FREDUN) Q3FY26 Management Mirror - Dec-2025 Qtr
Revenue & Financial Targets
Lowered: Management now projects a "comfortable" revenue target of 570-580 crores with a runway to 600 crores (Dec'25 Qtr). This represents a moderation from the Jun'25 Qtr ambition of doubling revenue to an 800+ crore top line within 3-4 years.
Reaffirmed: The "New Age" business (Generics, Pet Care, Nutraceuticals) is consistently targeted to contribute 51% of total business by FY29/FY30 (reiterated Dec'25 Qtr).
Modified: Specific FY26 segment projections were introduced in Dec'25 Qtr: Generics ~60 crores, Pet Care ~42 crores, Nutraceuticals ~26 crores. This adds granularity compared to the Jun'25 Qtr broad target of 15-20% YoY growth.
4 more themes on the ELITE plan.